Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

Cisplatin-based chemotherapy is the standard of care for patients with muscle invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Van Allen, Eliezer M., Mouw, Kent W., Kim, Philip, Iyer, Gopa, Wagle, Nikhil, Al-Ahmadie, Hikmat, Zhu, Cong, Ostrovnaya, Irina, Kryukov, Gregory V., O’Connor, Kevin W, Sfakianos, John, Garcia-Grossman, Ilana, Kim, Jaegil, Guancial, Elizabeth A., Bambury, Richard, Bahl, Samira, Gupta, Namrata, Farlow, Deborah, Qu, Angela, Signoretti, Sabina, Barletta, Justine A., Reuter, Victor, Boehm, Jesse, Lawrence, Michael, Getz, Gad, Kantoff, Philip, Bochner, Bernard H., Choueiri, Toni K., Bajorin, Dean F., Solit, David B., Gabriel, Stacey, D’Andrea, Alan, Garraway, Levi A., Rosenberg, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4238969/
https://ncbi.nlm.nih.gov/pubmed/25096233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0623
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados